Emergent BioSolutions | EBS - Debt


Emergent BioSolutions reported $903.2M in Debt for its fiscal quarter ending in June of 2023.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 1.57B 10.58M Sep/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amarin USD 0 0 Mar/2025
ANI Pharmaceuticals USD 607.23M 3.26M Sep/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Exelixis USD 162.2M 3.73M Sep/2026
Glaxosmithkline GBP 23.7B 4.65B Sep/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
Lonza CHF 4.71B 915M Dec/2024
Merck USD 53.91B 4.79B Jun/2026
Moderna USD 1.29B 11M Jun/2026
Myriad Genetics USD 59.3M 19.7M Mar/2025
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Pacira USD 293.59M 69.53M Sep/2026
Pfizer USD 62.67B 523M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Sanofi EUR 23.58B 3.56B Jun/2026
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024